Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.

Yun ShuHui LiHongjuan ShangJun ChenXiaoxing SuWei LeYan LeiLiming TaoCailiang ZouJiayan Wu

Published in: OncoTargets and therapy (2020)

The study identified a novel MPRIP-ROS1 fusion that was sensitive to crizotinib, which provided a new driver of lung adenocarcinoma and potential therapeutic target for crizotinib. It also expanded NSCLC treatment of ROS1 rearrangement and highlighted the importance of genetic testing for precise treatment decision-making.

Keyphrases

advanced non small cell lung cancer
cell death
dna damage
decision making
reactive oxygen species
combination therapy
oxidative stress
epidermal growth factor receptor
risk assessment
replacement therapy